

Glycoconjugate vaccine composition against *Salmonella* spp.

Domain: Vaccine

About Technology: A glycoconjugate vaccine (OSP-T2544) comprising of O-specific polysaccharide (OSP) from *Salmonella typhimurium* and the conserved outer membrane protein (T2544) of *Salmonella typhi/ paratyphi A* that induces humoral and cellular immunity and protects against *S. typhi*, *S. paratyphi A*, *S. typhimurium* and *S. enteritidis* infections in mice.

Intended Use: Candidate vaccine against Typhoidal and non-Typhoidal *Salmonella* infections

Advantages:

- Multivalent conjugate vaccine which induces strong seroconversion, secretory intestinal IgA response, and lasting immunological memory, offering protection against key *Salmonella* strains - Typhi, *S. paratyphi A*, *S. typhimurium* and *S. enteritidis*


IP Status: Filed (Indian Patent Application No. – 20231107021)

Development Status: Proof of concept established through in vitro and in vivo experiments, functional prototype developed

Technology Transfer Status: Transferred to companies on Non-Exclusive basis

Institute(s): ICMR- National Institute for Research in Bacterial Infections (NIRBI)

Inventor(s): Dr. Santasabuj Das, Dr. Risha Haldar, Dr. Amlanjyoti Dhar, Dr. Suparna Chakraborty



For Licensing Opportunities contact: patentmitra.hq@icmr.gov.in